The Briviact from UCB S.A. - targeted add-on for hard-to-treat epilepsy

Reviewed: ad hoc news B2B & Pro desk. Edited and checked on 2026-06-27, 02:43. Details in the imprint.

The Briviact from UCB S.A. sits in a small amber bottle on the clinician's desk, waiting for the moment when standard epilepsy drugs stop doing quite enough. The tablets feel smooth and dense between finger and foil, a reminder that this is a concentrated option for difficult cases.

Where Briviact fits in

Briviact is UCB's brivaracetam-based anti-seizure medicine, approved as add-on therapy for focal-onset seizures in patients from adolescence into adulthood when first-line regimens no longer control episodes sufficiently. It builds on the company's long experience with levetiracetam but targets the same SV2A protein with higher affinity.

For neurologists like Professor Jean-Michel Lagarde, who juggles multiple medicines for each patient, Briviact becomes the extra dial to turn when the combination of older agents starts to plateau, offering another chance to cut seizure frequency without completely overhauling the existing plan.

Dosing, forms and daily routine

In practice, Briviact is given as film-coated tablets, oral solution, or injectable formulations, allowing physicians to match the route to the patient's condition and ability to swallow safely. Typical adult doses are titrated over several days, layered gently on top of existing therapy so the body can adjust.

UCB's neurology team under Chief Medical Officer Dr. Iris Loew-Friedrich repeatedly stresses that Briviact is not a quick switch but a carefully managed addition, one that demands regular follow-up visits, blood work in selected cases, and frank conversations with patients about seizure diaries and mood changes.

What patients notice

Patients often describe Briviact as less intrusive than some older drugs, with fewer cognitive blurs in daily life when it is well matched to their regimen. A young adult might notice that the usual morning fog lifts faster, while a parent sees that conversations feel cleaner and less interrupted by searching for words.

Others, however, report irritability or fatigue, reminders that anti-epileptic medicines all carry trade-offs and that even a tidy tablet can alter how the brain orchestrates behaviour. Clinicians weigh these reports against seizure logs, adjusting doses or combinations to keep the balance tolerable and consistent.

Safety profile and monitoring

Briviact carries warnings familiar from other anti-epileptic drugs, including the potential for suicidal ideation and behavioural changes, so UCB's documentation asks physicians to screen patients for psychiatric history and to involve family members in monitoring. Liver function is also watched closely in certain populations.

In hospital settings, the injectable form gives teams flexibility when a patient cannot take oral medicines, yet protocols emphasise that any switch in route should be temporary and calculated, not improvisational. Briviact is part of a broader epilepsy strategy, not a standalone rescue tool.

Pricing and access

Briviact is positioned as a branded specialist medicine, with pricing reflecting its role in refractory or complex focal-onset epilepsy rather than first-line treatment. In Europe, reimbursement decisions typically hinge on neurologist guidelines and evidence of reduced seizure burden in defined patient groups.

CEO Jean-Christophe Tellier frames UCB's neurology portfolio, including Briviact, as a long-term commitment rather than a quick-margin franchise, arguing that consistent access and predictable supply help clinicians maintain trust in the brand even when newer molecules appear at conferences.

Regulatory footprint

Regulators in major markets, including the European Medicines Agency and the US Food and Drug Administration, have granted Briviact approval with post-marketing surveillance obligations. These require UCB to collect and analyse safety data, feeding updates into labelling documents and clinician alerts when patterns emerge.

That ongoing scrutiny means the language on Briviact's package inserts is not frozen. Over time, sections on interactions, special populations, and pregnancy considerations are updated, reflecting real-world experience rather than solely the controlled environment of pivotal trials.

Role in UCB's epilepsy line-up

Within UCB's portfolio, Briviact stands as a sibling to levetiracetam-based therapies, providing a more targeted SV2A interaction for patients who do not respond adequately or who struggle with tolerability on older agents. This layered strategy aims to keep clinicians inside one ecosystem as they adjust treatment.

For hospital pharmacists, that coherence simplifies ordering and counselling: they can walk through options bearing the same manufacturer imprint, explain why one product might step in after another, and keep storage and handling routines stable across the epilepsy shelf.

Stock and company context

All told, Briviact is a quietly robust pillar in UCB's neurology franchise, designed less to dominate headlines than to give specialists another precise lever for hard-to-treat focal epilepsy. UCB S.A. shares (ISIN BE0003739530) trade primarily on Euronext Brussels, where neurology revenues from products like Briviact anchor the company's valuation.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.